SYNERGY BETWEEN EBV AND HIV 1 DURING LYMPHOGENESIS

目前已知EB病毒(EBV)的宿主细胞范围 比最初认为的更广泛，现在包括B细胞 和上皮细胞，某些类型的T细胞。有人提议， 当同一个人 同时感染HIV-1和EBV以及EBV和HIV-1之间的协同作用 是有人建议的。之前我们已经证明了重叠的宿主细胞 Range导致HIV-1表达改变和EBV诱导的转化 混合感染的外周血淋巴细胞(PBL)和PBL亚群。 我们还检测到HIV-1的IIIB毒株与EBV之间的协同作用 在同种群CD19+B细胞感染过程中。许多 与不受控制的EBV复制相关的病理学方面有 在感染HIV-1期间表现出来。传统的想法是， EB病毒表达水平升高是T细胞减少的直接结果 监视系统。不受控制的EBV是EBV相关淋巴瘤的关键 去发展。这项提议的具体目的是使用既定的 一种新方法中的技术，以确定直接协同效应 EBV和HIV-1之间的关系发生在体内。具体地说，我们将使用 定量聚合酶链式反应和病毒拯救检测 EBV表达及检测CD3+、CD4+中HIV-1载量。CD8+、CD19+和 正常EBV血清阳性个体的单核/巨噬细胞和 感染HIV-1阳性患者的患者有无 淋巴瘤。淋巴瘤组将细分为与EBV相关的 与EBV无关。第二个研究小组将由个人组成 新诊断为HIV-1的人选择了标准干预措施 带和不带抗疱疹病毒治疗的抗逆转录病毒治疗。两者都有 将对群体进行纵向研究，具体目标是(I) 确定淋巴瘤的发生是否与病毒有关 负担，特别是淋巴细胞亚群，以及(Ii)确定 加或不加用抗疱疹病毒的抗逆转录病毒治疗效果观察 淋巴细胞亚群病毒载量的治疗。

The host cell range for Epstein-Barr virus (EBV) is now known to be much broader than originally believed and now includes, in addition to B cells and epithelial cells, some types of T cells. It has been proposed that accelerated disease progression might occur when the same individual is coinfected with both HIV-1 and EBV and synergy between EBV and HIV-1 has been suggested. Previously we have shown that overlapping host cell range resulted in altered HIV-1 expression and EBV-induced transformation in coinfected peripheral blood lymphocytes (PBLs) and PBL subpopulations. We have also detected synergy between the IIIB strain of HIV-1 and EBV during infection of homogeneous population of CD19+ B cells. Many aspects of pathology associated with uncontrolled EBV replication are manifested during HIV-1 infection. Conventional thought is that the elevated levels of EBV expression are the direct result of reduced T cell surveillance. Uncontrolled EBV is essential for EBV-associated lymphomas to develop. The specific aim of this proposal is to use established techniques in a novel approach to determine whether direct synergy between EBV and HIV-1 occurs in vivo. Specifically, we will use quantitative polymerase chain reaction (PCR) and virus rescue to detect EBV expression and measure HIV-1 load in CD3+, CD4+. CD8+, CD19+ and monocytes/macrophages from normal EBV-seropositive individuals and patients infected with HIV-1-positive individuals with and without lymphoma. The lymphoma group will be subdivided into EBV-associated with non-EBV-associated. The second study group will consist of individuals newly diagnosed as HIV-1 who have chosen intervention with standard antiretroviral therapy with and without anti-herpes virus therapy. Both groups will be studied longitudinally, with the specific aims of (i) determining whether lymphoma development can be correlated with viral burden in particular lymphocyte subpopulations, and (ii) determining the effects of antiretroviral therapy with or without anti-herpes virus therapy on viral burden in lymphocyte subpopulations.